Showing 15 posts of 243 posts found.


Lynparza tablets approved for NHS use in platinum-sensitive, BRCA-mutated ovarian, fallopian tube or peritoneal cancer

January 16, 2020
Sales and Marketing AstraZeneca, MSD, NHS, NICE, UK, lynparza

It has been announced that tablet form of Lynparza (olaparib), the PARP inhibitor developed by AstraZeneca and MSD, has secured …


MSD’s Keytruda chalks up bladder cancer approval in the US

January 9, 2020
Sales and Marketing Cancer, MSD, bladder cancer, keytruda, pharma

MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) has added another US approval to its repertoire with the news that FDA has awarded …


Bittersweet Phase 3 Keytruda data hits one of two goals in extensive stage small cell lung cancer

January 7, 2020
Manufacturing and Production, Research and Development MSD, keytruda

MSD has lifted the curtain on new Phase 3 data on the efficacy of its blockbuster immunotherapy Keytruda, in combination …


MSD set to acquire ArQule in deal worth up to $2.7 billion

December 10, 2019
Manufacturing and Production, Medical Communications, Sales and Marketing MSD, acquisition, arqule, pharma

MSD has revealed its intention to acquire biopharma firm ArQule in a deal worth a potential total of $2.7 billion, …


Keytruda overtakes Opdivo to lead sales in global immune checkpoint inhibitor market, report reveals

November 19, 2019
Manufacturing and Production, Sales and Marketing Bristol-Myers Squibb, MSD, keytruda, opdivo, pharma

MSD’s Keytruda (pembrolizumab) overtook Bristol-Myers Squibb’s (BMS) blockbuster drug Opdivo (nivolumab) in total sales in the third quarter of 2019 …


Bayer and MSD’s chronic heart failure drug meets main goal at Phase 3

November 19, 2019
Manufacturing and Production, Research and Development Bayer, MSD, pharma, vericiguat

MSD and Bayer have made it known that their jointly-developed soluble guanylate cyclase (sGC) stimulator vericiguat met its primary endpoint …


MSD’s proposed sale of French manufacturing plant puts over 200 jobs in jeopardy

November 14, 2019
Manufacturing and Production France, MSD, pharma

MSD has announced its plans to put its Centre de Mirabel production facility in Riom, France up for sale – …


MSD secures EU approval for its Zaire Ebola vaccine Ervebo

November 12, 2019
Manufacturing and Production, Sales and Marketing Ebola, Ervebo, MSD, pharma

MSD has scored approval from the European Commission for Ervebo, the company’s Zaire Ebola vaccine, for the prevention of Ebola …


MSD’s Keytruda approved for first-line lung cancer use on NHS Scotland

September 10, 2019
Manufacturing and Production, Sales and Marketing Cancer, MSD, SMC, Scotland, keytruda, lung cancer, pharma

MSD and lung cancer patients will be celebrating the news that the pharma giant’s immunotherapy Keytruda (pembrolizumab) has been accepted …


Keytruda scores EU approval in combination with Inlyta for first-line advanced renal cell carcinoma

September 4, 2019
Research and Development, Sales and Marketing EU, Europe, MSD, keytruda, pharma, renal cell carcinoma

The European Commission has awarded yet another authorisation in the region to MSD’s Keytruda, this time in combination with the …


FDA warns three Hepatitis C drugs may worsen liver function in some rare cases

August 29, 2019
Medical Communications, Research and Development AbbVie, FDA, Gilead, HCV, MSD, hepatitis C, public health

The FDA has warned that three Hepatitis C (HCV) drugs made by AbbVie, Gilead and MSD are worsening liver function …


HHS to fund production of MSD’s Ebola vaccine V920

August 22, 2019
Manufacturing and Production Ebola, HHS, MSD, Vaccine, pharma

The US Department of Health and Human Services (HHS) has said it will fund the production of MSD’s investigational Ebola …


Lynparza extends progression-free survival in first-line advanced ovarian cancer, with or without BRCA mutations

August 14, 2019
Research and Development AstraZeneca, Cancer, MSD, lynparza, ovarian cancer, pharma

New Phase 3 data has emerged on AstraZeneca and MSD’s Lynparza (olaparib), showing that the PARP inhibitor achieved its primary …


MSD teams up with Harvard University to discover novel immune system pathways to fight cancer

August 13, 2019
Manufacturing and Production, Research and Development Cancer, Harvard, MSD, Merck, immuno-oncology, oncology, pharma

A new partnership between MSD and Harvard University hopes to combine the expertise of both parties to carve a path …


Keytruda/chemo combo recommended for first-line lung cancer via Cancer Drugs Fund

August 8, 2019
Sales and Marketing CDF, Cancer, MSD, NHS, NICE, UK, keytruda, lung cancer, pharma

MSD’s Keytruda (pembrolizumab) has secured recommendation from NICE for inclusion on the Cancer Drugs Fund (CDF) in combination with chemotherapy …

Latest content